Peptideconjugation Antibody-peptide conjugates represent a rapidly advancing class of hybrid molecules designed to harness the specificity of antibodies for targeted delivery of peptide-based payloadsSpecific peptide conjugation to a therapeutic antibody .... These innovative constructs combine the exquisite targeting capabilities of antibodies, which can recognize specific antigens on disease cells, with the potent biological activity of peptides. This synergistic approach aims to enhance therapeutic efficacy while minimizing off-target effects, offering a promising new avenue for treating a wide range of conditions, particularly cancers and metabolic disordersAntibody–peptide conjugates deliver covalent inhibitors .... The development of antibody-peptide conjugates builds upon the success of antibody-drug conjugates (ADCs), seeking to leverage their advantages while potentially overcoming some of their limitationsAntibody-Peptide Conjugates Generation Service.
At their core, antibody-peptide conjugates are engineered molecules where a peptide sequence is covalently linked to an antibody.Antibody-peptide conjugation technologyuses chemical and biological methodsto create covalent connections between specific peptide segments and antibody ... The antibody component acts as a navigation system, directing the conjugate to specific cells or tissues expressing a particular target antigen. Once bound, the antibody facilitates the internalization of the conjugate into the cell, releasing the attached peptide payload.Antibody–drug conjugate This payload can then exert its therapeutic effect, whether by inhibiting specific enzymes, disrupting cellular processes, or modulating immune responses.
The design of these conjugates involves careful consideration of several key elements:
* Antibody Selection: The choice of antibody is critical and depends on the target disease. Antibodies that bind specifically to antigens overexpressed on cancer cells are commonly employedSite-Specific Chemical Conjugation of Antibodies by Using .... Nanobodies, smaller antibody fragments, are also being explored for their unique properties.Specific peptide conjugation to a therapeutic antibody ...
* Peptide Payload: The peptide component can be designed to carry various therapeutic functions. This includes enzyme inhibitors, signaling molecules, or peptides that can redirect immune cells. For instance, antibody-peptide inhibitor conjugates can deliver non-natural peptide inhibitors (NNPIs) directly to cancer cells, blocking the activity of oncogenic enzymes like cathepsins.
* Linker Technology: The linker connecting the antibody and peptide plays a crucial role in the stability, release kinetics, and overall efficacy of the conjugate. Linkers can be designed to be stable in circulation and cleavable within the target cell, ensuring payload release only at the desired site.Peptide-drug conjugates: A new paradigm for targeted ...
Antibody-peptide conjugates offer several compelling advantages over conventional treatments:
* Enhanced Specificity and Reduced Toxicity: By utilizing the targeting ability of antibodies, these conjugates can deliver therapeutic peptides directly to diseased cells, significantly reducing exposure of healthy tissues to the active agentAntibody-peptide conjugation technologyuses chemical and biological methodsto create covalent connections between specific peptide segments and antibody .... This targeted approach can lead to fewer systemic side effects compared to administering unbound peptides or systemic drugs.
* Improved Pharmacokinetics and Potency: Conjugation can alter the pharmacokinetic profile of peptides, often increasing their half-life and improving their stability in the body. This can lead to sustained therapeutic effects and potentially allow for less frequent dosing.2024年3月27日—The modality of MariTide'santibody-peptide conjugatedetermines its longer half-life compared to peptides and small molecule drugs. The ongoing ... Furthermore, the enhanced therapeutic potency seen with some antibody-peptide conjugates is attributed to factors like reduced Fc dynamics, leading to improved stability.
* Overcoming Peptide Limitations: Many peptides, when administered alone, suffer from poor stability, rapid clearance from the body, and limited tissue penetration.Antibody–drug conjugate Antibody conjugation can help overcome these limitations, making peptides a more viable therapeutic option2025年7月10日—MariTide induced weight loss, ranging from 12.1%–17%, in individuals living with obesity and type 2 diabetes, compared to a 1.4% reduction with placebo..
* Next-Generation Therapeutics: Peptide-drug conjugates (PDCs), which often involve peptides delivering small molecule drugs, are emerging as a novel trend, positioned as the next generation of targeted therapeutics after ADCs. Antibody-peptide conjugates share this forward-looking perspective, representing a sophisticated evolution in drug design.
The most prominent application area for antibody-peptide conjugates is oncology. By targeting tumor-specific antigens, these conjugates can deliver cytotoxic peptides or molecules that inhibit tumor growth and metastasis. For example, antibody-peptide inhibitor conjugates provide a promising solution for targeting specific cell types and blocking critical enzymatic activities within cancer cellsDevelopment Progress and Prospects of Antibody-Peptide .... They can also be designed to redirect T-cell viral immunity against tumor cells, a novel approach in cancer immunotherapy.
Beyond cancer, antibody-peptide conjugates hold potential in treating other diseases:
* Metabolic Disorders: Conjugates designed to target receptors involved in metabolic regulation are being investigated for conditions like obesity and type 2 diabetes. For instance, certain antibody-peptide conjugates have demonstrated significant weight loss in preclinical and early clinical studies.
* Autoimmune Diseases: By targeting specific immune cells or inflammatory mediators, these conjugates could offer targeted therapies for autoimmune conditions with fewer immunosuppressive side effects.
The development of antibody-peptide conjugates involves complex chemical and biological methods to ensure precise conjugation. Advances in site-specific conjugation techniques are crucial for creating homogeneous conjugates with predictable properties. As the field matures, we can expect to see a growing number of antibody-peptide conjugates entering clinical trials and eventually reaching patients作者：S Zhang·2022·被引用次数：17—Antibody–peptide epitope conjugates (APEC) are a new class of modified antibody–drug conjugates thatredirect T-cell viral immunity against tumor cells.. The ongoing research into novel linker technologies, peptide payloads, and antibody engineering will continue to expand the therapeutic potential of these versatile molecular constructs, solidifying their role as a key modality in precision medicine作者：K Jadhav·2025·被引用次数：19—PDCs offer several advantages over antibody–drug conjugates (ADCs), includingsmaller size for deeper tissue penetration, faster clearance reducing off-target ....
Join the newsletter to receive news, updates, new products and freebies in your inbox.